Genentech/Novartis/Tanox Xolair
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
April 26 Pulmonary-Allergy Drugs Advisory Committee meeting at which Xolair was to be reviewed has been cancelled. The firms say they expect to launch the asthma and allergic rhinitis therapy omalizumab "in the latter part of 2001." The Xolair BLA was filed in June 200